Gluten sensitivity — formally termed non-coeliac gluten sensitivity (NCGS) — is one of the most discussed and debated conditions in modern gastroenterology. Millions of people report that reducing gluten in their diet improves their digestive symptoms and overall wellbeing. Unlike coeliac disease, NCGS does not cause villous atrophy or measurable intestinal damage. Unlike wheat allergy, it is not IgE-mediated. What it does cause — in a meaningful proportion of people — is a constellation of GI and extra-intestinal symptoms that respond to gluten avoidance. The science behind exactly why remains actively debated, but the clinical experience is real and the management approach is practical.
What Is Gluten and Where Is It Found?
Gluten is the collective name for storage proteins in three grains: gliadin and glutenin in wheat; hordein in barley; and secalin in rye. It provides the elastic texture of bread and pasta. Beyond obvious sources, gluten appears in many processed and packaged foods — sometimes unexpectedly.
Common gluten-containing foods: bread, pasta, pizza, crackers, pastries, cakes, most breakfast cereals, beer (barley malt), malt vinegar, soy sauce (wheat-fermented), most gravy and stock products, processed soups and sauces.
Hidden sources: medication coatings, some supplements, licorice, seasoning mixes, processed meats (binders), imitation seafood products.
Naturally gluten-free grains: rice, corn, oats (if certified gluten-free), millet, quinoa, amaranth, buckwheat, sorghum, teff, cassava.
Note on “ancient grains”: spelt, kamut, triticale, bulgur, and farro all contain gluten despite sometimes being marketed as more digestible alternatives. They are not safe for people with coeliac disease or NCGS.
What Is Gluten Sensitivity?
NCGS is defined as a clinical syndrome in which intestinal and extra-intestinal symptoms are triggered by gluten ingestion in individuals in whom coeliac disease and wheat allergy have been formally excluded. Key features: normal anti-tTG IgA, normal total IgA, and normal or minimally abnormal duodenal histology (Marsh 0–1; no villous atrophy).
The underlying mechanism remains incompletely understood. Current evidence points to several contributors:
- Innate immune activation: elevated IL-15 and other innate immune markers in NCGS patients — distinct from the adaptive T-cell response in coeliac disease
- Amylase-trypsin inhibitors (ATIs): non-gluten wheat proteins that activate TLR4 on gut macrophages, promoting innate inflammation; may account for some symptoms attributed to “gluten” in NCGS patients
- FODMAPs / fructans: a landmark 2013 double-blind crossover study (Gastroenterology, Biesiekierski et al.) found that in people on a low-FODMAP diet, isolated gluten did not worsen symptoms vs placebo — suggesting fructan (the FODMAP in wheat, barley, onion, garlic) may be the actual driver of symptoms in a significant subset of NCGS patients
- Intestinal permeability: some studies show mildly increased permeability in NCGS, with potential systemic immune effects; evidence is inconsistent
Symptoms of Gluten Sensitivity
Gastrointestinal: abdominal bloating (often the dominant symptom — rapid post-meal distension); cramping or diffuse abdominal pain; nausea; diarrhoea, constipation, or alternating bowel habits; excess flatulence. These overlap considerably with IBS.
Extra-intestinal symptoms: fatigue; “brain fog” (difficulty concentrating, impaired working memory, mental haziness — consistently the most distressing non-GI symptom in NCGS patients); headache and migraine; musculoskeletal symptoms (joint pain, myalgia); mood changes including irritability and low mood; skin symptoms (eczema, non-specific rash); tingling or numbness in the extremities.
Symptom timeline: NCGS symptoms develop hours to days after gluten ingestion (not minutes, as in wheat allergy) and resolve over days to weeks on a GFD. This slow onset/offset is consistent with innate immune or FODMAP-mediated mechanisms rather than IgE.
How Gluten Sensitivity Is Diagnosed
Starting a GFD before serological testing will normalise anti-tTG IgA and make coeliac disease impossible to diagnose without a prolonged gluten challenge. Coeliac disease must be excluded first — while you are still eating gluten normally.
NCGS has no validated diagnostic biomarker — diagnosis is based on exclusion and clinical response:
Step 1 — Exclude coeliac disease: anti-tTG IgA + total serum IgA (on a normal gluten-containing diet). If negative with normal total IgA, coeliac disease is unlikely. OGD + biopsy follows if positive serology. For the full coeliac diagnostic pathway, see our article on celiac disease: symptoms and diagnosis.
Step 2 — Exclude wheat allergy: wheat-specific IgE blood test and/or skin prick test. Negative result excludes IgE-mediated wheat allergy.
Step 3 — 6–8 week GFD trial: structured diet trial with systematic symptom monitoring. Improvement supports NCGS diagnosis.
Step 4 — Gluten challenge (Salerno Experts’ Criteria, 2015): blinded re-challenge with gluten versus placebo distinguishes true gluten reactivity from IBS, FODMAPs, or nocebo effect. Not universally performed in clinical practice but important for diagnostic rigour.
For initial evaluation of the GI symptoms prompting investigation, see our overviews of when stomach pain needs evaluation and functional dyspepsia explained.
Gluten Sensitivity vs Coeliac Disease vs Wheat Allergy
Mechanism: coeliac = T-cell autoimmune (adaptive immunity); NCGS = innate immunity, ATIs, possibly FODMAPs; wheat allergy = IgE-mediated immediate hypersensitivity.
Onset after wheat ingestion: coeliac disease accumulates damage over years; NCGS symptoms develop hours to days after exposure; wheat allergy reacts within minutes to hours.
Testing: coeliac has confirmed biomarkers (anti-tTG IgA, Marsh 3 biopsy); NCGS has no validated biomarker (exclusion diagnosis); wheat allergy confirmed by wheat-specific IgE/skin prick test.
Mucosal damage: coeliac causes Marsh 3 villous atrophy and malabsorption; NCGS causes no significant mucosal damage; wheat allergy causes no chronic mucosal damage.
Long-term risk: coeliac carries risk of EATL, osteoporosis, small bowel adenocarcinoma; NCGS does not cause these complications; wheat allergy carries anaphylaxis risk.
Dietary threshold: coeliac requires strict <20 ppm GFD for life; NCGS can often be managed with practical gluten reduction (not trace-level elimination); wheat allergy requires wheat avoidance in all forms.
The FODMAPs and NCGS Debate
The 2013 Biesiekierski et al. study (Gastroenterology) challenged the simple narrative that gluten directly causes symptoms in all NCGS patients. In a methodologically rigorous double-blind crossover trial, participants with self-reported NCGS who were on a low-FODMAP background diet did not show significantly more symptoms with added gluten compared to placebo. This raised the possibility that fructan — the fermentable carbohydrate in wheat — rather than gliadin is the actual trigger in a large subset of patients labelled as gluten-sensitive.
The clinical implication is significant: many patients diagnosed or self-diagnosing with NCGS may actually have fructan (FODMAP) intolerance. For these patients, a low-FODMAP diet — which reduces wheat, barley, onion, garlic, and other fructan-rich foods — may produce more sustained and flexible symptom relief than a strict GFD. The two conditions can also coexist.
Subsequent research has confirmed that both effects likely exist: some patients have genuine gluten-mediated innate immune activation; others have fructan sensitivity; and some have both. The practical approach is to test the GFD first (as it is more accessible to patients), then consider a low-FODMAP assessment if GFD produces only partial benefit. Dietitian-guided evaluation can distinguish these mechanisms and avoid unnecessary long-term dietary restriction. According to a systematic review in Nutrients (Catassi et al., 2017), NCGS remains an active research area and the diagnostic and mechanistic picture continues to evolve.
Managing Gluten Sensitivity
GFD trial (6–8 weeks): if both coeliac and wheat allergy have been excluded, a structured GFD is the appropriate first step. Monitor symptoms systematically — ideally with a symptom diary rather than a global impression.
FODMAPs / fructan assessment: if GFD produces only partial benefit, or if patients want to understand the mechanism better, a supervised low-FODMAP trial with dietitian guidance is valuable. Wheat fructans are present in many of the same foods as gluten, making differentiation difficult without structure.
Dietary threshold: unlike coeliac disease, NCGS does not require trace-level (<20 ppm) avoidance of gluten. Practical reduction of dietary gluten is the primary goal. Cross-contamination at parts-per-million level is unlikely to be clinically relevant for most NCGS patients — though individual sensitivity varies.
Nutritional considerations: a GFD can reduce intake of fibre, iron, folate, and B vitamins if gluten-containing grains are replaced with refined gluten-free alternatives. Replacement with naturally gluten-free whole grains (quinoa, buckwheat, millet, certified oats) maintains nutritional quality. Dietitian guidance ensures nutritional adequacy on a long-term GFD.
Reassessment over time: some NCGS patients find their sensitivity reduces after gut microbiome stabilisation on a GFD. Supervised periodic reintroduction trials can determine individual thresholds and prevent unnecessary long-term dietary restriction.
The Role of Gut Microbiome in Gluten and Wheat Sensitivity
The gut microbiome is emerging as an important factor in understanding why some people with genetic and immunological profiles similar to the general population develop symptomatic responses to gluten or wheat while others do not. The small intestinal and colonic microbiome influences intestinal permeability, FODMAP fermentation patterns, mucosal innate immune tone, and the gut-brain axis — all of which are implicated in NCGS pathophysiology.
Several observations link microbiome alterations to NCGS and wheat sensitivity. First, patients with NCGS show altered microbiome composition compared to healthy controls — specifically, reduced beneficial bacteria such as Bifidobacterium and Faecalibacterium prausnitzii (key butyrate-producing anti-inflammatory organisms), and a relative enrichment of pro-inflammatory species. Second, fructan — the FODMAP in wheat that current evidence suggests may be a primary driver of symptoms in many NCGS patients — is fermented primarily by Bifidobacterium species in the proximal colon. When Bifidobacterium populations are depleted, fructan fermentation becomes less efficient and more gas-producing, contributing to bloating and cramping. Third, altered microbiome composition affects intestinal tight junction protein expression, influencing the degree of mucosal permeability through which wheat-derived peptides and ATIs may reach the lamina propria.
The therapeutic implication is that optimising the gut microbiome — through dietary diversity, prebiotic intake (paradoxically, including some fructan-containing foods in tolerable amounts after a period of reduction), and in some cases targeted probiotic supplementation — may improve tolerance to gluten-containing and wheat-containing foods over time. This is a more mechanistically sophisticated approach than simply eliminating wheat indefinitely, and aligns with the growing body of evidence showing that NCGS symptoms can improve over months to years in many patients without lifelong strict avoidance.
Practical Guidance for Eating Out and Travelling with Gluten Sensitivity
One of the practical challenges of NCGS is managing social eating — restaurants, travel, family meals, and work functions where dietary control is limited. Unlike coeliac disease, where any cross-contamination at the parts-per-million level is clinically significant, NCGS allows more flexibility — but practical reduction in dietary gluten still requires planning, particularly in situations where wheat appears in unexpected forms.
For restaurant dining, the most useful approach is to focus on naturally gluten-free whole food choices — grilled meats, fish, vegetables, rice, and potato dishes — rather than relying on specially prepared “gluten-free” options (which may not always be necessary for NCGS and may carry a premium cost). Sauces and seasonings are the primary hidden risk: most Western commercial sauces contain wheat starch or modified wheat starch as a thickener. Plain preparation (grilled or steamed without sauce) is the most reliable option in unfamiliar settings.
When travelling internationally, it is worth noting that wheat-based staple foods vary considerably by region. Travelling in East Asia, for example, naturally involves much less wheat consumption than in Western Europe or the Middle East. Many traditional cuisines in Sub-Saharan Africa, the Caribbean, and South and Southeast Asia are predominantly rice- or root vegetable-based, making them naturally lower in gluten. Awareness of regional cuisine patterns can inform destination choices and preparation for travel.
Communication cards — pre-printed in the local language explaining the need to avoid wheat, barley, and rye — are available from several coeliac and food sensitivity organisations and are valuable tools for international travel, even though the medical standard for NCGS is somewhat less strict than for confirmed coeliac disease.
When to Seek Medical Assessment for Suspected Gluten Sensitivity
Self-diagnosing gluten sensitivity and self-initiating a gluten-free diet — without formal medical assessment — is extremely common, but carries the risk of missing a more significant diagnosis. The most important condition to exclude is coeliac disease, which requires lifelong strict GFD, specific nutritional monitoring, and bone density assessment. A patient who self-starts a GFD based on symptom response alone, without first testing for coeliac disease, has permanently compromised their ability to receive an accurate diagnosis without undertaking a formal gluten challenge (typically 10g of gluten per day for 6 weeks) — which many patients find too symptomatically difficult to complete.
Beyond coeliac disease, several other conditions can present with gluten-like symptom responses and warrant medical investigation before NCGS is assumed. Iron deficiency anaemia — particularly if recurrent or poorly responsive to oral supplementation — may indicate small bowel malabsorption from coeliac disease, inflammatory bowel disease, or chronic blood loss from another GI source. Diarrhoea with weight loss, particularly if accompanied by abdominal pain, requires colonoscopy to exclude inflammatory bowel disease or malignancy. Persistent bloating in a patient over 50 should prompt clinical review rather than immediate dietary self-management, as ovarian or colorectal pathology can present similarly.
The practical recommendation is: if you have GI symptoms that you believe are related to gluten or wheat, see a GP before making dietary changes. Request anti-tTG IgA + total serum IgA testing, which is inexpensive, widely available, and can definitively confirm or refute coeliac disease as a likely diagnosis. If results are negative and wheat allergy is excluded, a supervised GFD trial under dietitian guidance is the appropriate next step. This sequence costs very little and preserves all diagnostic options. Skipping it in favour of immediate dietary self-management closes those options and may delay a genuinely important diagnosis by years.
Gluten Sensitivity and Related Skin Conditions
Skin symptoms are among the more commonly reported extra-intestinal manifestations of wheat and gluten sensitivity, though the mechanisms differ considerably between conditions. The most clearly established skin-gut connection in gluten-related disease is dermatitis herpetiformis (DH) — the specific skin manifestation of coeliac disease, confirmed by IgA deposition in the dermis on skin biopsy. However, DH does not occur in NCGS — it is exclusive to coeliac disease.
In NCGS, the skin symptoms reported by patients are more varied and less specific: eczema, psoriasis flares, non-specific urticarial rashes, and generalised skin sensitivity. The mechanisms are proposed to involve systemic innate immune activation leading to inflammatory skin responses, and possibly gut-derived inflammatory mediators reaching the skin via altered intestinal permeability. The relationship between NCGS and eczema or psoriasis has not been confirmed in controlled studies, but many patients report improvement in skin symptoms on a GFD — consistent with the broader pattern of systemic innate immune normalisation on gluten avoidance.
It is important to distinguish between these non-specific skin responses in NCGS and the specific IgE-mediated skin reactions of wheat allergy (urticaria, angioedema, contact dermatitis occurring within hours of wheat exposure). If skin reactions occur rapidly after wheat ingestion — within minutes to hours — wheat-specific IgE testing is the appropriate next step to exclude wheat allergy before attributing symptoms to NCGS.
Frequently Asked Questions
Yes — NCGS is a clinically recognised condition endorsed by major gastroenterology societies. However, “gluten sensitivity” as popularly understood encompasses several distinct mechanisms: true innate immune reactions to wheat proteins, ATI-mediated inflammation, FODMAP/fructan sensitivity, and in some cases IBS with nocebo effects. What is consistent is that many people genuinely experience symptom improvement on a GFD, and this is not simply psychological. Identifying which mechanism is operative changes the optimal management — which is why a structured diagnostic approach is important.
Coeliac disease can only be excluded by anti-tTG IgA + total IgA blood testing, and where positive, duodenal biopsy — both performed while on a normal gluten-containing diet. NCGS has normal serology and histology. You cannot distinguish between them by dietary response alone — both improve on a GFD. Testing must come first. Coeliac disease requires lifelong strict GFD and ongoing monitoring for nutritional deficiencies; NCGS does not. The distinction matters for long-term management.
Some patients find their sensitivity diminishes over time, particularly when symptoms are primarily FODMAP-driven (FODMAP tolerance can improve with gut rehabilitation and microbiome stabilisation). Unlike coeliac disease, NCGS does not cause progressive mucosal damage, so the long-term consequences of gradual reintroduction are lower. Supervised reintroduction trials after 6–12 months on a GFD are a reasonable approach to determine individual threshold. Whether “true” innate immune-mediated NCGS can resolve over time is less clear.
No. In people without coeliac disease or NCGS, a GFD has no demonstrated health benefit and may have nutritional disadvantages — commercially available GF products are often lower in fibre and higher in sugar and fat than their wheat-containing equivalents. For the general population, wholegrain wheat is associated with cardiovascular and metabolic health benefits. A GFD is a therapeutic intervention for specific diagnoses, not a universal health improvement strategy.
“Gluten brain fog” describes cognitive symptoms consistently reported by NCGS patients: difficulty concentrating, impaired short-term memory, mental fatigue, and a subjective sense of mental haziness that improves on a GFD. The mechanism is not established — proposed explanations include systemic innate immune activation affecting neurological function, gut-brain axis signalling, and microbiome-mediated effects. In confirmed coeliac disease, neurological manifestations (gluten neuropathy, gluten ataxia) are well-established. In NCGS, the mechanism is less certain but the symptom is consistently validated in observational studies.
Yes. A subset of NCGS patients present primarily or exclusively with extra-intestinal symptoms — fatigue, brain fog, musculoskeletal pain, mood changes, or skin symptoms — with minimal or no GI complaints. This presentation is less intuitive and less likely to prompt investigation for NCGS. It likely reflects systemic innate immune or neurological effects of wheat components rather than localised intestinal responses.
Not necessarily. Coeliac disease requires strict <20 ppm gluten avoidance because even trace amounts perpetuate villous atrophy and carry long-term cancer and nutritional risks. NCGS does not cause villous atrophy, so the consequence of occasional gluten exposure is symptomatic discomfort rather than structural damage or progressive disease. Most NCGS patients find that substantially reducing dietary gluten — without trace-level vigilance — is sufficient for symptom control. Individual sensitivity varies, and some patients with NCGS do react to very low amounts, but trace-level elimination is not universally necessary.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always exclude coeliac disease with appropriate testing before starting a gluten-free diet.
References
- Catassi C et al. Non-Celiac Gluten Sensitivity: The New Frontier of Gluten Related Disorders. Nutrients. 2013;5(10):3839–3853. Available at: PubMed.
- Biesiekierski JR et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320–328. Available at: PubMed.
- Catassi C et al. Diagnosis of non-celiac gluten sensitivity (NCGS): The Salerno Experts’ Criteria. Nutrients. 2015;7(6):4966–4977. Available at: PubMed.
- Skodje GI et al. Fructan, rather than gluten, induces symptoms in patients with self-reported NCGS. Gastroenterology. 2018;154(3):529–539. Available at: PubMed.
- NHS. Gluten sensitivity (non-coeliac). Available at: nhs.uk.
The section about the FODMAPs debate completely changed how I think about my own ‘gluten sensitivity.’ I’ve been avoiding gluten for 3 years and always assumed it was the gluten specifically. Reading about the fructan hypothesis and the Biesiekierski study makes me wonder if I should try a low-FODMAP approach instead. Has anyone found this more effective than a full GFD?
That’s a great question, Natasha — and it’s exactly the kind of reassessment that the current evidence supports. If you’ve been on a GFD for 3 years and want to understand whether gluten itself or fructan is the driver, the ideal approach would be to work with a dietitian who specialises in low-FODMAP protocols. They can guide a structured reintroduction phase that gradually reintroduces gluten-containing foods while controlling fructan loads separately, which can clarify your specific trigger. The FODMAP-tolerant approach would give you far more dietary flexibility if it turns out fructan rather than gluten is the main issue.
Really important point about getting tested for coeliac disease BEFORE starting a gluten-free diet. I wish someone had told me this — I started a GFD on my own based on symptoms and then when I did get the blood test months later it was negative, and my doctor said they couldn’t rule out coeliac without a gluten challenge. I wasn’t willing to do that. So I still don’t know definitively. Please do the testing first.